- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Patent holdings for IPC class A61P 9/10
Total number of patents in this class: 9164
10-year publication summary
|
282
|
271
|
378
|
536
|
476
|
558
|
608
|
520
|
513
|
453
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Daiichi Sankyo Company, Limited | 1879 |
125 |
| The Regents of the University of California | 20245 |
74 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3370 |
71 |
| Osaka University | 3388 |
62 |
| Shionogi & Co., Ltd. | 838 |
57 |
| Takeda Pharmaceutical Company Limited | 2719 |
53 |
| Novartis AG | 10635 |
51 |
| Sunshine Lake Pharma Co., Ltd. | 600 |
49 |
| Bristol-myers Squibb Company | 4833 |
46 |
| Amarin Pharmaceuticals Ireland Limited | 272 |
45 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 840 |
42 |
| Bayer Pharma AG | 1048 |
39 |
| Mitsubishi Tanabe Pharma Corporation | 558 |
38 |
| AstraZeneca AB | 2854 |
37 |
| Kowa Company, Ltd. | 1202 |
35 |
| Centre National de La Recherche Scientifique | 10645 |
32 |
| Institut National de La Sante et de La Recherche Medicale (inserm) | 2958 |
32 |
| University of Pittsburgh - Of the Commonwealth System of Higher Education | 3208 |
32 |
| Boehringer Ingelheim International GmbH | 4644 |
31 |
| The Johns Hopkins University | 5746 |
31 |
| Other owners | 8182 |